A Study to Evaluate Immunotherapy and Ovarian Function Among Pre-menopausal Melanoma Survivors


About this study

The purposes of this study are to analyze the ovarian function of female premenopausal melanoma survivors who have undergone immunotherapy, and compare with data from age-matched controls, prospectively investigate ovarian function in premenopausal women with melanoma undergoing immunotherapy, and to identify the impact of ovarian function change on the frequency and function of CD8+ T cells during immunotherapy.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Cohort 1:
    • Women 40 or under diagnosed with melanoma (Stage III or above), 1-5 years from diagnosis, either received immunotherapy with anti-PD1 agent (n=20), or received no immunotherapy (n=20).
  • Cohort 2:
    • Women 40 or under diagnosed with melanoma and plan to undergo immunotherapy with anti-PD1 agent (n=20).

Exclusion Criteria: 

  • Women under 18 years of age.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Yiyi Yan, M.D., Ph.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office


More information


Publications are currently not available

Mayo Clinic Footer